Search results for "immunoglobulin G"

showing 10 items of 308 documents

Anti-HLA alloantibodies of the IgA isotype in re-transplant candidates part II: Correlation with graft survival

2017

We reported previously on the widespread occurrence of anti-HLA alloantibodies of the IgA isotype (anti-HLA IgA) in the sera of solid-organ re-transplantation (re-tx) candidates (Arnold et al., ). Specifically focussing on kidney re-tx patients, we now extended our earlier findings by examining the impact of the presence and donor specificity of anti-HLA IgA on graft survival. We observed frequent concurrence of anti-HLA IgA and anti-HLA IgG in 27% of our multicenter collective of 694 kidney re-tx patients. This subgroup displayed significantly reduced graft survival as evidenced by the median time to first dialysis after transplantation (TTD 77 months) compared to patients carrying either …

Male0301 basic medicinemedicine.medical_treatmentMedizinHistocompatibility Testing030230 surgery0302 clinical medicineAntibody SpecificityHLA AntigensIsoantibodiesMedicineChildGenetics (clinical)Aged 80 and overKidneybiologyGraft SurvivalGeneral MedicineMiddle AgedPrognosisIsotypemedicine.anatomical_structureChild PreschoolRetreatmentFemaleAntibodyAdultAdolescentImmunologyHuman leukocyte antigenYoung Adult03 medical and health sciencesGeneticsHumansMolecular BiologyAllelesDialysisAgedbusiness.industryOrgan TransplantationKidney TransplantationTransplant RecipientsImmunoglobulin ATransplantation030104 developmental biologyImmunoglobulin GImmunologybiology.proteinGraft survivalbusinessInternational Journal of Immunogenetics
researchProduct

Comparison of a rapid immunochromatographic test with a chemiluminescence immunoassay for detection of anti-SARS-CoV-2 IgM and IgG

2020

Introduction: The 2019 Coronavirus disease (COVID-19) has been characterized as a pandemic, representing a serious global public health emergency. Serological tests have been proposed as reliable tools for detecting Coronavirus SARS-CoV-2 antibodies in infected patients, especially for surveillance or epidemiological purposes. The aim of this study is to evaluate the agreement between the IgM/IgG rapid assays, based on lateral flow immunochromatographic assay, and the fully automated 2019-nCoV IgM and IgG, based on chemiluminescence immunoassay. Materials and methods: SARS-CoV-2 antibodies were measured with the BIOSYNEX COVID-19 BSS IgM/IgG test (BIOSYNEX, Illkirch-Graffenstaden, France) a…

Male030213 general clinical medicineClinical BiochemistryAntibodies Viralmedicine.disease_causeLikelihood ratios in diagnostic testinglaw.inventionSerologyCOVID-19 Testing0302 clinical medicinelawantibodiesMedicineCoronavirusImmunoassay0303 health sciencesbiologymedicine.diagnostic_testMiddle AgedantibodiePopulation SurveillanceFemaleAntibodyCLIACoronavirus InfectionsShort CommunicationConcordanceSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralBetacoronavirus03 medical and health sciencesimmunochromatographyHumansPandemicsAged030304 developmental biologyChemiluminescenceClinical Laboratory TechniquesSARS-CoV-2business.industryCOVID-19; serological test; antibodies; CLIA; immunochromatographyBiochemistry (medical)Reproducibility of ResultsCOVID-19serological testImmunoglobulin MImmunoglobulin GImmunoassayLuminescent MeasurementsImmunologybiology.proteinbusiness
researchProduct

Antiphospholipid antibodies in pediatric patients with prolonged activated partial thromboplastin time during infection.

2005

Abstract Objective To investigate the close association between different antiphospholipid antibodies (aPL) caused by infection and their appearance together with a prolonged activated partial thromboplastin time (aPTT). Methods Sera from 122 children were evaluated in this study. Thirty-seven children with mild to medium prolonged aPTT (>37.2 s) and elevated C-reactive protein (CRP) levels during various forms of infections (group 2), 18 children without infections (group 3) but with mild to medium prolonged aPTT and 13 children with infections (group 4) and with elevated CRP-level as well as a control group (group 1) of 54 patients without any infection and normal aPTT and negative CRP le…

MaleAdolescentFeverImmunologyInfectionsImmunoglobulin Gchemistry.chemical_compoundCardiolipinmedicineImmunology and AllergyHumansChildLupus anticoagulantbiologymedicine.diagnostic_testbusiness.industryC-reactive proteinInfantHematologyPhosphatidylserinemedicine.diseaseC-Reactive ProteinchemistryImmunoglobulin MImmunoglobulin MChild PreschoolImmunoglobulin GImmunologybiology.proteinAntibodies AntiphospholipidFemalePartial Thromboplastin TimeAntibodybusinessPartial thromboplastin timeImmunobiology
researchProduct

Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population.

2005

Abstract German adolescents ( n  = 123) without previous pertussis vaccination, no history of pertussis and low IgG-anti-pertussis-toxin (PT) levels received one dose of the Tdap vaccine Boostrix™. Blood samples were taken before, and 5–12 days and 29–49 days after vaccination. IgG- and IgA-anti-PT, IgG- and IgA-anti filamentous hemagglutinin, IgG-anti-pertactin, IgG-anti-tetanus-toxin, and IgG-anti-diphtheria-toxin were measured by ELISA. 88.6% of subjects had an immune response to PT, and all vaccinees had an immune response to at least one pertussis antigen 29–49 days after vaccination. IgA-anti-PT and IgA-anti-FHA responses were found in 43 and 81% of subjects, respectively. This study …

MaleAdolescentWhooping CoughFilamentous haemagglutinin adhesinDiphtheria-Tetanus-acellular Pertussis VaccinesBordetella pertussisImmune systemAntigenImmunitymedicineHumansWhooping coughImmunization ScheduleAntigens BacterialGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityPublic Health Environmental and Occupational Healthmedicine.diseaseVirologyAntibodies BacterialVaccinationInfectious DiseasesImmunoglobulin GImmunologyMolecular MedicineFemalebusinessAcellular pertussisVaccine
researchProduct

The diagnostic significance of IgG cow's milk protein antibodies re-evaluated

1996

The effect of different feeding regimens, notably the use of hydrolysed cow's milk formulas, on the development of allergic reactions and the development of cow's milk protein-IgG antibodies is still disputed. We prospectively compared the development of allergic manifestations and cow's milk protein-IgG antibodies in a total of 702 infants who were divided into six groups: Cow's milk protein antibodies were determined by an indirect immuno-fluorescent test. Antibody titres rose slowly in groups 1, 3 and 6. Children in group 5 showed two high peaks. There were no significant differences in the frequency and type of allergic manifestations between the groups. Introduction of cow's milk formu…

MaleAllergyBreast milkImmune systemImmunopathologymedicineAnimalsHumansProspective StudiesFluorescent Antibody Technique Indirectbiologybusiness.industryAge FactorsInfantfood and beveragesMilk Proteinsmedicine.diseaseBottle FeedingFood intoleranceInfant formulaImmunoglobulin GPediatrics Perinatology and Child HealthImmunologybiology.proteinCattleFemaleMilk HypersensitivityAntibodybusinessBreast feedingEuropean Journal of Pediatrics
researchProduct

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

2010

The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and disease modifying antirheumatic drugs in quite a number of patients. Tumor necrosis factor inhibitors have demonstrated to be of value in reducing AS disease activity in clinical trials. The efficacy and safety of both etanercept and infliximab in patients with ankylosing spondylitis were compared in a 2-year open label randomised study. Our results are consistent with a significant more rapid clinical improvement in the infliximab treated group. Treatment with both etanercept and infliximab at the end of the study was effective, safe, and well tolerated. ©…

MaleAntibodieReceptors Tumor Necrosis FactorEtanerceptlaw.inventionEtanerceptRandomized controlled triallawimmune system diseasesOutcome Assessment Health CareMonoclonalImmunology and Allergyskin and connective tissue diseasesAntirheumatic AgentAntibodies MonoclonalAntirheumatic AgentsTreatment OutcomeAntirheumatic AgentsFemalemedicine.drugHumanReceptormusculoskeletal diseasesAdultAnkylosingmedicine.medical_specialtyImmunologyDrug Administration ScheduleOutcome Assessment (Health Care)RheumatologyInternal medicinemedicineHumansSpondylitis AnkylosingSpondylitisSpondylitiAnkylosing spondylitisbusiness.industryTumor Necrosis Factor-alphaAnkylosing spondylitis; Etanercept; Infliximab; Adult; Antibodies Monoclonal; Antirheumatic Agents; Drug Administration Schedule; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Male; Outcome Assessment (Health Care); Receptors Tumor Necrosis Factor; Spondylitis Ankylosing; Treatment Outcome; Tumor Necrosis Factor-alpha; Rheumatology; Immunology; Immunology and Allergymedicine.diseaseInfliximabRheumatologyInfliximabClinical trialAnkylosing spondylitistomatognathic diseasesImmunoglobulin GPhysical therapybusinessTumor Necrosis Factor
researchProduct

Kinetics of antibodies and antigens in serum of mice experimentally infected with echinostoma caproni (trematoda: echinostomatidae)

2005

The present study reports on the kinetics of antibodies and antigens in serum of mice experimentally infected with 75 metacercariae of Echinostoma caproni during the first 12 wk postinfection (wpi). Antibody titers in the serum of mice were determined by an indirect enzyme-linked immunosorbent assay (ELISA) using excretory/secretory (ES) antigens of E. caproni. The early detection of antibodies against ES antigens of E. caproni is feasible using indirect ELISA. Mice developed significant antibody responses at 2 wpi, and the values progressively increased until the end of the experiment. This may be related to the intestinal absorption of adult worm antigens that induces humoral responses. T…

MaleAntibodies HelminthEnzyme-Linked Immunosorbent AssayEchinostoma caproniImmunoglobulin GIntestinal absorptionAntibodies:CIENCIAS DE LA VIDA [UNESCO]MicrobiologyMiceAntigenEchinostomaUNESCO::CIENCIAS DE LA VIDAAnimalsAntigensEcology Evolution Behavior and SystematicsEchinostomiasisMice Inbred ICRbiologyBiomphalariaAntibody titer:CIENCIAS DE LA VIDA::Biología animal (Zoología) ::Parasitología animal [UNESCO]biology.organism_classificationUNESCO::CIENCIAS DE LA VIDA::Biología animal (Zoología) ::Parasitología animalDisease Models AnimalKineticsPolyclonal antibodiesAntibodies ; Antigens ; Echinostoma caproniAntigens HelminthImmunoglobulin GImmunologybiology.proteinParasitologyTrematodaEchinostomaAntibody
researchProduct

Reactogenicity of a three-dose pertussis acellular vaccine catch-up in children 21-40 months of age

1999

Abstract The reactogenicity of a three-dose catch-up acellular pertussis (aP) immunization of children at 21–40 months of age was evaluated. Vaccination was well-tolerated: fever ≥38°C was reported after 5% of administered doses and local reactions after 14–15%. The onset of adverse events was not associated with age at vaccination, interval between doses or previous presence of antibodies against pertussis, whereas injection in sites other than the buttock and presence of the same symptom after a previous dose were associated with higher reactogenicity. Because of the good safety profile of primary aP immunization in children >1 year of age, catch-up vaccination campaigns could be consider…

MaleBordetella pertussisPediatricsmedicine.medical_specialtyAgingDose-Response Relationship ImmunologicBordetella pertussisMedicineHumansAdverse effectWhooping coughImmunization SchedulePertussis VaccineReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybiologybusiness.industryVaccinationPublic Health Environmental and Occupational HealthInfantbiology.organism_classificationmedicine.diseaseAntibodies BacterialVaccinationInfectious DiseasesImmunizationEl NiñoChild PreschoolImmunoglobulin GToxicityImmunologyMolecular MedicineFemalebusiness
researchProduct

Structural and functional characterization of a human IgG monoclonal antiphospholipid antibody

2009

Antiphospholipid antibodies (aPL) are likely involved in the pathogenesis of the antiphospholipid syndrome (APS). This study analyzes the structural and functional characteristics of a human monoclonal aPL (HL7G) from the IgG2 subtype with λ light chains generated from a patient with primary APS and recurrent cerebral microemboli. DNA encoding the variable region of heavy and light chains of the antibody was sequenced, analyzed, and compared to HL5B a previously described monoclonal aPL from the same patient. Both antibodies are derived from the same germline genes. HL7G had similar but more extensive somatic mutations in the CDR1 and 2 regions than HL5B, indicating that both antibodies are…

MaleCardiolipinsmedicine.drug_classImmunologySomatic hypermutationComplementarity determining regionMonoclonal antibodyImmunoglobulin light chainThromboplastinAntigenimmune system diseasesAntiphospholipid syndromemedicineHumansImmunology and AllergyneoplasmsCells CulturedMolecular StructurebiologyAntibodies MonoclonalT-Lymphocytes Helper-InducerHematologyMiddle AgedAntiphospholipid Syndromemedicine.diseaseComplementarity Determining RegionsMolecular biologybeta 2-Glycoprotein IImmunoglobulin GImmunologyMonoclonalAntibodies Antiphospholipidbiology.proteinSomatic Hypermutation ImmunoglobulinAntibodyImmunobiology
researchProduct

Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term…

2002

Abstract Immunoglobulin G (IgG) antibody titres against pertussis antigens, Bordetella pertussis-specific proliferation and cytokine production by peripheral blood mononuclear cells (PBMCs) were evaluated at the age of 5–6 years in 13 children who had been pre-term infants with a gestational age (GA) of ≤31 weeks, 10 who had been pre-term infants with a GA of 32–37 weeks, and 15 who had been term infants with a GA of 38–42 weeks. All of the infants had been immunised with a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine (DTaP–HBV) at 3, 5, and 11 months of post-natal age. Our results show that the long-term immune responses induced by primary pertussi…

MaleCellular immunityBordetella pertussisTime FactorsHepatitis B vaccineWhooping CoughImmunization SecondaryIn Vitro TechniquesLymphocyte ActivationBordetella pertussisPertussismedicineHumansHepatitis B VaccinesChildDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleWhooping coughHaemophilus VaccinesImmunity CellularPre-term infantsGeneral VeterinaryGeneral Immunology and MicrobiologybiologyTetanusbusiness.industryDiphtheriaDTaP-HBV vaccine; Pertussis; Pre-term infantsAge FactorsInfant NewbornPublic Health Environmental and Occupational Healthmedicine.diseasebiology.organism_classificationAntibodies BacterialVaccinationInfectious DiseasesCase-Control StudiesChild PreschoolImmunoglobulin GImmunologybiology.proteinDTaP-HBV vaccineCytokinesMolecular MedicineFemaleAntibodybusinessInfant PrematureVaccine
researchProduct